Advanced/Metastatic

Oncology·MeSH: Neoplasm Metastasis

16 drugs in development·10 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
eftilagimod alfa	Immutep Limited (IMMP)
eftilagimod alfa	IMMUTEP Ltd (PRRUF)
Eftilagimod Alfa	Immutep Limited (IMMP)
rigosertib	TRAWS PHARMA, INC. (ONTX)
SYS6010	Merus N.V. (MRUS)
tak-788	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-788	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(6)

Drug	Company
ALLO-316	Allogene Therapeutics, Inc. (ALLO)
ALLO-647	Allogene Therapeutics, Inc. (ALLO)
Cyclophophamide	Allogene Therapeutics, Inc. (ALLO)
Fludarabine	Allogene Therapeutics, Inc. (ALLO)
sarilumab	REGENERON PHARMACEUTICALS, INC. (REGN)
ubamatamab	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 1(2)

Drug	Company
amg 510	AMGEN INC (AMGN)
kzr-261	Kezar Life Sciences, Inc. (KZR)

Phase 1/Phase 2(1)

Drug	Company
regn7075	REGENERON PHARMACEUTICALS, INC. (REGN)

BioSniper tracks 16 drugs in development for Advanced/Metastatic across 10 companies.

There are 2 clinical trials targeting Advanced/Metastatic tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.